Stockscreener 앱 받기
2.44
1.24%
0.03
시간 외 거래:
2.45
0.01
+0.41%
Gain Therapeutics Inc 주식(GANX)의 최신 뉴스
Is Zentalis Pharmaceuticals Inc. stock ready for breakoutGap Up & Low Risk Profit Maximizing Plans - ulpravda.ru
Is Gain Therapeutics Inc. stock supported by strong fundamentalsJuly 2025 Momentum & Low Risk Growth Stock Ideas - ulpravda.ru
Published on: 2026-01-09 02:02:08 - ulpravda.ru
Can Gain Therapeutics Inc. stock reach $100 price target2025 Earnings Surprises & Daily Profit Maximizing Tips - ulpravda.ru
Can Gain Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Movers & Technical Buy Zone Confirmations - ulpravda.ru
Gain Therapeutics, Inc. to Participate in Key Events During 44th Annual J.P. Morgan Healthcare Conference Week - Quiver Quantitative
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
GANX: GT-02287 reduced GluSph by 81% and improved motor scores in Parkinson's disease patients - TradingView — Track All Markets
Gain Therapeutics reports 81% reduction in Parkinson’s biomarker By Investing.com - Investing.com Australia
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 - The Manila Times
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update - MarketBeat
Research Analysts’ Weekly Ratings Changes for Gain Therapeutics (GANX) - Defense World
Roth/MKM raises Gain Therapeutics stock price target to $10 on positive trial data - Investing.com Australia
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why - Yahoo Finance
Roth/MKM raises Gain Therapeutics stock price target to $10 on positive trial data By Investing.com - Investing.com South Africa
Gain Therapeutics Sees Stock Surge Amid Positive Clinical Results and Ambitious Price Target Increase - StocksToTrade
Is Gain Therapeutics Inc. stock a smart buy before Fed meeting2025 Investor Takeaways & Expert Curated Trade Setup Alerts - Улправда
Gain Therapeutics (GANX) Price Target Increased by 11.76% to 7.75 - Nasdaq
Gain Therapeutics’ (GANX) Buy Rating Reaffirmed at HC Wainwright - Defense World
HC Wainwright & Co. Reiterates Gain Therapeutics (GANX) Buy Recommendation - Nasdaq
US Market Wrap: Why Gain Therapeutics Inc. stock could see breakout soonJuly 2025 Retail & Weekly High Return Forecasts - Улправда
Can Gain Therapeutics Inc. stock sustain institutional interestJuly 2025 News Drivers & Community Consensus Stock Picks - Улправда
GANX - Finviz
Can Gain Therapeutics Inc. stock weather global recession2025 Analyst Calls & AI Powered Buy and Sell Recommendations - Улправда
Earnings Recap: Is Gain Therapeutics Inc. stock a smart buy before Fed meetingWeekly Loss Report & Growth Focused Stock Reports - Улправда
Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright - MarketBeat
Weekly Recap: Is Gain Therapeutics Inc. stock a smart buy before Fed meetingInsider Buying & Expert Approved Trade Ideas - Улправда
Why Gain Therapeutics Inc. stock attracts high net worth investors2025 Risk Factors & High Return Trade Guides - DonanımHaber
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease - The Manila Times
Why Gain Therapeutics Inc. stock could see breakout soon2025 Investor Takeaways & Community Shared Stock Ideas - Улправда
Early signals stack up: Two small molecules activate GCase in Parkinson’s - biocentury.com
Parkinson's experts to unpack new GT-02287 biomarker data Jan. 6 - Stock Titan
Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data - TipRanks
Gain Therapeutics Announces Phase 1b Study Results for GT-02287 - TradingView — Track All Markets
[8-K] Gain Therapeutics, Inc. Reports Material Event | GANX SEC FilingForm 8-K - Stock Titan
Gain Therapeutics Reports First-Ever Reduction of Glucosylsphingosine in CSF of Parkinson's Disease Patients in Phase 1b Study of GT-02287 - Quiver Quantitative
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease - The Manila Times
Early Parkinson's study links spinal fluid change to brain enzyme shift - Stock Titan
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Trade Recap: Will Atossa Therapeutics Inc stock gain from lower inflationJuly 2025 Chart Watch & Weekly Chart Analysis and Guides - moha.gov.vn
AI and Physics-Based Modeling Identifies a New Parkinson’s Disease Drug - the-scientist.com
Here's why Gain Therapeutics, Inc. (GANX) is a great momentum stock to buy - MSN
Gain Therapeutics At A Crossroads: Will GT-02287 Deliver Disease-Modifying Proof? - RTTNews
How sustainable is Gain Therapeutics Inc stock dividend payoutProfit Target & Consistent Growth Equity Picks - moha.gov.vn
Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy - sharewise.com
Gain Therapeutics Inc (GANX) expanding its growth trajectory ahead - setenews.com
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
0.80%
4.56%
자본화:
|
볼륨(24시간):